HomeRegistrationPresentationsFacultyRefer a ColleagueArchives


Session 1: The science to inform our decision making

Where are we now, what are our key challenges?

Professor Jeremy Chapman
Westmead Hospital, Australia

Immunoregulation and tolerance

Dr. Stuart J. Knechtle
Emory University School of Medicine, USA

Session 2: Reviewing the clinical evidence – considering the role of calcineurin inhibitors

Can the early elimination of CNIs bring clinical benefits?

Dr. Matthew R. Weir
University of Maryland Hospital, Baltimore, Maryland, USA

Long-term maintenance with CNIs – an update

Professor Josep M. Campistol
Hospital Clinic, University of Barcelona, Spain

Can we eliminate both CNIs and steroids?

Professor Yvon Lebranchu
University Hospital of Tours, France

Session 3: New immunosuppressive agents in kidney transplantation

Considerations for new immunosuppressive combinations: A clinical perspective

Professor Lionel Rostaing
Toulouse University Hospital, France

Session 4: Post-transplant malignancy

Can immunosuppressive strategies be used to reduce the risk of cancer in renal transplant patients?

Professor Edward K. Geissler
University of Regensburg, Germany

Session 5: The non-immunosuppressive properties of mTOR-inhibition

Regression of left ventricular hypertrophy in kidney transplant recipients – the potential role for mTOR-inhibition

Dr. Ernesto Paoletti
San Martino University Hospital, Genoa, Italy

mTOR-inhibition and impact on autosomal dominant polycystic kidney disease

Professor Rudolf P. Wüthrich
University Hospital, Zürich, Switzerland

Session 6: Conclusions from the symposium

Conclusions from the symposium

Professor Josep M. Campistol
Hospital Clinic, University of Barcelona, Spain